0

Close
 
2022
Conjunctivitis Treatment Market

Conjunctivitis Treatment Market

by Drug Class (Antibiotics, Antiviral, Anti-allergic, Artificial Tears), by Disease Type (Allergic Conjunctivitis, Bacterial Conjunctivitis, Viral Conjunctivitis), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2021-2031

LS : Pharmaceuticals
Report Code: A17599
Sep 2022 | Pages: 220
Tables: 190
Charts: 67

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

Conjunctivitis Treatment Market Research, 2031

The global conjunctivitis treatment market was valued at $4.2 billion in 2021 and is projected to reach $6.1 billion by 2031, growing at a CAGR of 3.8% from 2022 to 2031. Conjunctivitis is an inflammation of the membrane covering the surface of the eyeball. It can be a result of infection or irritation of the eye. A membrane called the conjunctiva covers the surface of the eyeball and the interior of the eyelids. Conjunctival irritation from allergens is possible, especially during the hay fever season. Allergy-related conjunctivitis is highly common. It is an individual body's response to compounds that it perceives as potentially hazardous

The COVID-19 pandemic has negatively impacted the conjunctivitis treatment market. COVID-19 affected the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others faced problems with regards to transportation of drugs from one place to another. Furthermore, players operating in the global conjunctivitis treatment market faced major challenges on various fronts due to the COVID-19 pandemic. Major challenges included the supply of raw materials required for manufacturing drug formulations due to irregularities in transportation. Moreover, distributors experienced irregular demand for products from the retailers due to an increase in the number of patients suffering from COVID-19 and other life-threatening disorders.

Conjunctivitis Treatment Market

Conjunctivitis caused by allergens is more common in those with allergies. According to the Asthma and Allergy Foundation of America, allergies run in families and impact 30% of adults and 40% of children. Common signs of allergic conjunctivitis include red, watery, burning, and itchy eyes. An increase in the patient population of allergic conjunctivitis worldwide and escalating demand for healthcare services is expected to majorly drive the growth of the Conjunctivitis Treatment Market size. In addition, many key market players are focusing on R&D activities to develop drugs for allergic conjunctivitis as the patient population is increasing, which also drives the conjunctivitis treatment market growth. The key factors such as environmental factors, pathogens, and growing exposure to pollutants contribute to the increase in the prevalence of conjunctivitis.

Moreover, an increase in R&D activity for advancements in conjunctivitis treatment, and product approvals contribute to the growth of the Conjunctivitis Treatment Industry. For instance, in October 2021, Ocular Therapeutix, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, received the U.S. Food and Drug Administration (FDA) Supplemental New Drug Application (sNDA) approval for its to broaden the DEXTENZA. Thus, the latest product approvals by regulating authorities contribute to the growth of the market.

The growing interest of manufacturers & developers in the development of conjunctivitis treatment and the latest product launch drives the growth of the Conjunctivitis Treatment Market size. For instance, in February 2021, Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced the U.S. launch of Alaway preservative-free (ketotifen fumarate ophthalmic solution 0.035%) antihistamine eye drops. In addition, combined manufacturers' efforts for developing footprints in emerging market contributes to the growth of the market.

The conjunctivitis treatment market is segmented into Drug Class, Disease Type, and Distribution Channel.

By disease type segment market is divided into allergic conjunctivitis, bacterial conjunctivitis, and viral conjunctivitis. Allergic conjunctivitis is further divided into seasonal allergic conjunctivitis and perennial allergic conjunctivitis. Depending on drug class is classified into antibiotics, antiviral, anti-allergic, and artificial tears. According to the distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy.

By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Arabia, South Africa, and LAMEA).

Segment Review

Depending on disease type, the allergic conjunctivitis segment dominated the market in 2021, and this trend is expected to continue during the forecast period, owing to advancements in conjunctivitis treatment and increasing exposures to allergens. However, the viral conjunctivitis segment is expected to witness considerable growth during the forecast period, due to an increase in the prevalence of viral eye infections and the latest product launch in the market.

Conjunctivitis Treatment Market

Based on drug class, the anti-allergic segment dominated the market in 2021, and this trend is expected to continue during the forecast period, owing to the increasing prevalence of allergic conjunctivitis and a rise in exposure to allergens. However, the antiviral segment is expected to witness considerable growth during the forecast period, due to an increase in the prevalence of viral conjunctivitis and a rise in R&D activities for the development of advanced drugs.

Conjunctivitis Treatment Market

By distribution channel, the hospital pharmacy segment dominated the market in 2021, and this trend is expected to continue during the Conjunctivitis Treatment Market forecast period, owing to the rise in the number of hospital pharmacies and an increase in demand for advanced treatment. However, the retail pharmacy segment is expected to witness considerable growth during the forecast period, due to an increase in the number of retail pharmacy stores and a rise in healthcare expenditures.

Conjunctivitis Treatment Market

Depending on the region, North America garnered the major share in the conjunctivitis treatment market in 2021 and is expected to dominate the global Conjunctivitis Treatment Market share during the forecast period owing to the presence of well-established healthcare infrastructure, advancements in conjunctivitis treatment, and presence of key players. However, Asia-Pacific is expected to register significant growth, owing to an increase in product launches in the region, a rise in healthcare expenditures, and the presence of a high population base.

Conjunctivitis Treatment Market

The key players operating in the global conjunctivitis treatment market AbbVie Inc., Ajanta Pharma Limited, AFT pharmaceuticals, Alembic Pharmaceuticals Ltd, Bausch Health Companies Inc, Cipla, Inc., Grevis Pharmaceutical Private Limited, Indoco Remedies Ltd., Jabs Biotech Pvt. Ltd., JAWA Pharmaceuticals Pvt. Ltd, Johnson & Johnson Services Inc., , Novartis AG, Ocular Therapeutics, Inc., Santen Pharmaceuticals Co. Ltd., Spectra Vision Care Pvt. Ltd, Sun Pharmaceuticals Industries Ltd, and Teva Pharmaceutical Industries Ltd.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the conjunctivitis treatment market analysis from 2021 to 2031 to identify the prevailing Conjunctivitis Treatment Market opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the conjunctivitis treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global conjunctivitis treatment market trends, key players, market segments, application areas, and market growth strategies.

 Conjunctivitis Treatment Market Report Highlights

Aspects Details
Market Size By 2031 USD 6.1 billion
Growth Rate CAGR of 3.8%
Forecast period 2021 - 2031
Report Pages 220
By Drug Class
  • Antibiotics
  • Antiviral
  • Anti-allergic
  • Artificial Tears
By Disease Type
  • Allergic Conjunctivitis
    • Type
      • Seasonal Allergic Conjunctivitis
      • Perennial Allergic Conjunctivitis
  • Bacterial Conjunctivitis
  • Viral Conjunctivitis
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (Japan, China, Australia, India, South Korea, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players Grevis Pharmaceutical Private Limited, Bausch Health Companies Inc, JAWA Pharmaceuticals Pvt. Ltd, Sun Pharmaceuticals Industries Ltd, Ocular Therapeutics, Inc, Teva Pharmaceutical Industries Ltd, Cipla, Inc., Indoco Remedies Ltd., Alembic Pharmaceuticals Ltd, Jabs Biotech Pvt. Ltd., Johnson & Johnson Services Inc, Spectra Vision Care Pvt. Ltd, Abbvie Inc, Novartis AG, Ajanta Pharma Limited, Santen Pharmaceuticals Co. Ltd., AFT Pharmaceuticals
 

  • CHAPTER 1:INTRODUCTION

    • 1.1.Report description

    • 1.2.Key market segments

    • 1.3.Key benefits to the stakeholders

    • 1.4.Research Methodology

      • 1.4.1.Secondary research

      • 1.4.2.Primary research

      • 1.4.3.Analyst tools and models

  • CHAPTER 2:EXECUTIVE SUMMARY

    • 2.1.Key findings of the study

    • 2.2.CXO Perspective

  • CHAPTER 3:MARKET OVERVIEW

    • 3.1.Market definition and scope

    • 3.2.Key findings

      • 3.2.1.Top investment pockets

    • 3.3.Porter’s five forces analysis

    • 3.4.Top player positioning

    • 3.5.Market dynamics

      • 3.5.1.Drivers

      • 3.5.2.Restraints

      • 3.5.3.Opportunities

    • 3.6.COVID-19 Impact Analysis on the market

  • CHAPTER 4: CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS

    • 4.1 Overview

      • 4.1.1 Market size and forecast

    • 4.2 Antibiotics

      • 4.2.1 Key market trends, growth factors and opportunities

      • 4.2.2 Market size and forecast, by region

      • 4.2.3 Market analysis by country

    • 4.3 Antiviral

      • 4.3.1 Key market trends, growth factors and opportunities

      • 4.3.2 Market size and forecast, by region

      • 4.3.3 Market analysis by country

    • 4.4 Anti-allergic

      • 4.4.1 Key market trends, growth factors and opportunities

      • 4.4.2 Market size and forecast, by region

      • 4.4.3 Market analysis by country

    • 4.5 Artificial Tears

      • 4.5.1 Key market trends, growth factors and opportunities

      • 4.5.2 Market size and forecast, by region

      • 4.5.3 Market analysis by country

  • CHAPTER 5: CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE

    • 5.1 Overview

      • 5.1.1 Market size and forecast

    • 5.2 Allergic Conjunctivitis

      • 5.2.1 Key market trends, growth factors and opportunities

      • 5.2.2 Market size and forecast, by region

      • 5.2.3 Market analysis by country

      • 5.2.4 Allergic Conjunctivitis Conjunctivitis Treatment Market by Type

        • 5.2.4.1 Seasonal Allergic Conjunctivitis Market size and forecast, by region
        • 5.2.4.2 Perennial Allergic Conjunctivitis Market size and forecast, by region

    • 5.3 Bacterial Conjunctivitis

      • 5.3.1 Key market trends, growth factors and opportunities

      • 5.3.2 Market size and forecast, by region

      • 5.3.3 Market analysis by country

    • 5.4 Viral Conjunctivitis

      • 5.4.1 Key market trends, growth factors and opportunities

      • 5.4.2 Market size and forecast, by region

      • 5.4.3 Market analysis by country

  • CHAPTER 6: CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

    • 6.1 Overview

      • 6.1.1 Market size and forecast

    • 6.2 Hospital Pharmacy

      • 6.2.1 Key market trends, growth factors and opportunities

      • 6.2.2 Market size and forecast, by region

      • 6.2.3 Market analysis by country

    • 6.3 Retail Pharmacy

      • 6.3.1 Key market trends, growth factors and opportunities

      • 6.3.2 Market size and forecast, by region

      • 6.3.3 Market analysis by country

    • 6.4 Online Pharmacy

      • 6.4.1 Key market trends, growth factors and opportunities

      • 6.4.2 Market size and forecast, by region

      • 6.4.3 Market analysis by country

  • CHAPTER 7: CONJUNCTIVITIS TREATMENT MARKET, BY REGION

    • 7.1 Overview

      • 7.1.1 Market size and forecast

    • 7.2 North America

      • 7.2.1 Key trends and opportunities

      • 7.2.2 North America Market size and forecast, by Drug Class

      • 7.2.3 North America Market size and forecast, by Disease Type

        • 7.2.3.1 North America Allergic Conjunctivitis Conjunctivitis Treatment Market by Type

      • 7.2.4 North America Market size and forecast, by Distribution Channel

      • 7.2.5 North America Market size and forecast, by country

        • 7.2.5.1 U.S.
          • 7.2.5.1.1 Market size and forecast, by Drug Class
          • 7.2.5.1.2 Market size and forecast, by Disease Type
          • 7.2.5.1.3 Market size and forecast, by Distribution Channel
        • 7.2.5.2 Canada
          • 7.2.5.2.1 Market size and forecast, by Drug Class
          • 7.2.5.2.2 Market size and forecast, by Disease Type
          • 7.2.5.2.3 Market size and forecast, by Distribution Channel
        • 7.2.5.3 Mexico
          • 7.2.5.3.1 Market size and forecast, by Drug Class
          • 7.2.5.3.2 Market size and forecast, by Disease Type
          • 7.2.5.3.3 Market size and forecast, by Distribution Channel

    • 7.3 Europe

      • 7.3.1 Key trends and opportunities

      • 7.3.2 Europe Market size and forecast, by Drug Class

      • 7.3.3 Europe Market size and forecast, by Disease Type

        • 7.3.3.1 Europe Allergic Conjunctivitis Conjunctivitis Treatment Market by Type

      • 7.3.4 Europe Market size and forecast, by Distribution Channel

      • 7.3.5 Europe Market size and forecast, by country

        • 7.3.5.1 Germany
          • 7.3.5.1.1 Market size and forecast, by Drug Class
          • 7.3.5.1.2 Market size and forecast, by Disease Type
          • 7.3.5.1.3 Market size and forecast, by Distribution Channel
        • 7.3.5.2 France
          • 7.3.5.2.1 Market size and forecast, by Drug Class
          • 7.3.5.2.2 Market size and forecast, by Disease Type
          • 7.3.5.2.3 Market size and forecast, by Distribution Channel
        • 7.3.5.3 UK
          • 7.3.5.3.1 Market size and forecast, by Drug Class
          • 7.3.5.3.2 Market size and forecast, by Disease Type
          • 7.3.5.3.3 Market size and forecast, by Distribution Channel
        • 7.3.5.4 Italy
          • 7.3.5.4.1 Market size and forecast, by Drug Class
          • 7.3.5.4.2 Market size and forecast, by Disease Type
          • 7.3.5.4.3 Market size and forecast, by Distribution Channel
        • 7.3.5.5 Spain
          • 7.3.5.5.1 Market size and forecast, by Drug Class
          • 7.3.5.5.2 Market size and forecast, by Disease Type
          • 7.3.5.5.3 Market size and forecast, by Distribution Channel
        • 7.3.5.6 Rest of Europe
          • 7.3.5.6.1 Market size and forecast, by Drug Class
          • 7.3.5.6.2 Market size and forecast, by Disease Type
          • 7.3.5.6.3 Market size and forecast, by Distribution Channel

    • 7.4 Asia-Pacific

      • 7.4.1 Key trends and opportunities

      • 7.4.2 Asia-Pacific Market size and forecast, by Drug Class

      • 7.4.3 Asia-Pacific Market size and forecast, by Disease Type

        • 7.4.3.1 Asia-Pacific Allergic Conjunctivitis Conjunctivitis Treatment Market by Type

      • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel

      • 7.4.5 Asia-Pacific Market size and forecast, by country

        • 7.4.5.1 Japan
          • 7.4.5.1.1 Market size and forecast, by Drug Class
          • 7.4.5.1.2 Market size and forecast, by Disease Type
          • 7.4.5.1.3 Market size and forecast, by Distribution Channel
        • 7.4.5.2 China
          • 7.4.5.2.1 Market size and forecast, by Drug Class
          • 7.4.5.2.2 Market size and forecast, by Disease Type
          • 7.4.5.2.3 Market size and forecast, by Distribution Channel
        • 7.4.5.3 Australia
          • 7.4.5.3.1 Market size and forecast, by Drug Class
          • 7.4.5.3.2 Market size and forecast, by Disease Type
          • 7.4.5.3.3 Market size and forecast, by Distribution Channel
        • 7.4.5.4 India
          • 7.4.5.4.1 Market size and forecast, by Drug Class
          • 7.4.5.4.2 Market size and forecast, by Disease Type
          • 7.4.5.4.3 Market size and forecast, by Distribution Channel
        • 7.4.5.5 South Korea
          • 7.4.5.5.1 Market size and forecast, by Drug Class
          • 7.4.5.5.2 Market size and forecast, by Disease Type
          • 7.4.5.5.3 Market size and forecast, by Distribution Channel
        • 7.4.5.6 Rest of Asia-Pacific
          • 7.4.5.6.1 Market size and forecast, by Drug Class
          • 7.4.5.6.2 Market size and forecast, by Disease Type
          • 7.4.5.6.3 Market size and forecast, by Distribution Channel

    • 7.5 LAMEA

      • 7.5.1 Key trends and opportunities

      • 7.5.2 LAMEA Market size and forecast, by Drug Class

      • 7.5.3 LAMEA Market size and forecast, by Disease Type

        • 7.5.3.1 LAMEA Allergic Conjunctivitis Conjunctivitis Treatment Market by Type

      • 7.5.4 LAMEA Market size and forecast, by Distribution Channel

      • 7.5.5 LAMEA Market size and forecast, by country

        • 7.5.5.1 Brazil
          • 7.5.5.1.1 Market size and forecast, by Drug Class
          • 7.5.5.1.2 Market size and forecast, by Disease Type
          • 7.5.5.1.3 Market size and forecast, by Distribution Channel
        • 7.5.5.2 Saudi Arabia
          • 7.5.5.2.1 Market size and forecast, by Drug Class
          • 7.5.5.2.2 Market size and forecast, by Disease Type
          • 7.5.5.2.3 Market size and forecast, by Distribution Channel
        • 7.5.5.3 South Africa
          • 7.5.5.3.1 Market size and forecast, by Drug Class
          • 7.5.5.3.2 Market size and forecast, by Disease Type
          • 7.5.5.3.3 Market size and forecast, by Distribution Channel
        • 7.5.5.4 Rest of LAMEA
          • 7.5.5.4.1 Market size and forecast, by Drug Class
          • 7.5.5.4.2 Market size and forecast, by Disease Type
          • 7.5.5.4.3 Market size and forecast, by Distribution Channel

  • CHAPTER 8: COMPANY LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top winning strategies

    • 8.3. Product Mapping of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Key developments

  • CHAPTER 9: COMPANY PROFILES

    • 9.1 Abbvie Inc

      • 9.1.1 Company overview

      • 9.1.2 Company snapshot

      • 9.1.3 Operating business segments

      • 9.1.4 Product portfolio

      • 9.1.5 Business performance

      • 9.1.6 Key strategic moves and developments

    • 9.2 Ajanta Pharma Limited

      • 9.2.1 Company overview

      • 9.2.2 Company snapshot

      • 9.2.3 Operating business segments

      • 9.2.4 Product portfolio

      • 9.2.5 Business performance

      • 9.2.6 Key strategic moves and developments

    • 9.3 AFT Pharmaceuticals

      • 9.3.1 Company overview

      • 9.3.2 Company snapshot

      • 9.3.3 Operating business segments

      • 9.3.4 Product portfolio

      • 9.3.5 Business performance

      • 9.3.6 Key strategic moves and developments

    • 9.4 Alembic Pharmaceuticals Ltd

      • 9.4.1 Company overview

      • 9.4.2 Company snapshot

      • 9.4.3 Operating business segments

      • 9.4.4 Product portfolio

      • 9.4.5 Business performance

      • 9.4.6 Key strategic moves and developments

    • 9.5 Bausch Health Companies Inc

      • 9.5.1 Company overview

      • 9.5.2 Company snapshot

      • 9.5.3 Operating business segments

      • 9.5.4 Product portfolio

      • 9.5.5 Business performance

      • 9.5.6 Key strategic moves and developments

    • 9.6 Cipla, Inc.

      • 9.6.1 Company overview

      • 9.6.2 Company snapshot

      • 9.6.3 Operating business segments

      • 9.6.4 Product portfolio

      • 9.6.5 Business performance

      • 9.6.6 Key strategic moves and developments

    • 9.7 Grevis Pharmaceutical Private Limited

      • 9.7.1 Company overview

      • 9.7.2 Company snapshot

      • 9.7.3 Operating business segments

      • 9.7.4 Product portfolio

      • 9.7.5 Business performance

      • 9.7.6 Key strategic moves and developments

    • 9.8 Indoco Remedies Ltd.

      • 9.8.1 Company overview

      • 9.8.2 Company snapshot

      • 9.8.3 Operating business segments

      • 9.8.4 Product portfolio

      • 9.8.5 Business performance

      • 9.8.6 Key strategic moves and developments

    • 9.9 Jabs Biotech Pvt. Ltd.

      • 9.9.1 Company overview

      • 9.9.2 Company snapshot

      • 9.9.3 Operating business segments

      • 9.9.4 Product portfolio

      • 9.9.5 Business performance

      • 9.9.6 Key strategic moves and developments

    • 9.10 JAWA Pharmaceuticals Pvt. Ltd

      • 9.10.1 Company overview

      • 9.10.2 Company snapshot

      • 9.10.3 Operating business segments

      • 9.10.4 Product portfolio

      • 9.10.5 Business performance

      • 9.10.6 Key strategic moves and developments

    • 9.11 Johnson & Johnson Services Inc

      • 9.11.1 Company overview

      • 9.11.2 Company snapshot

      • 9.11.3 Operating business segments

      • 9.11.4 Product portfolio

      • 9.11.5 Business performance

      • 9.11.6 Key strategic moves and developments

    • 9.12 Novartis AG

      • 9.12.1 Company overview

      • 9.12.2 Company snapshot

      • 9.12.3 Operating business segments

      • 9.12.4 Product portfolio

      • 9.12.5 Business performance

      • 9.12.6 Key strategic moves and developments

    • 9.13 Ocular Therapeutics, Inc

      • 9.13.1 Company overview

      • 9.13.2 Company snapshot

      • 9.13.3 Operating business segments

      • 9.13.4 Product portfolio

      • 9.13.5 Business performance

      • 9.13.6 Key strategic moves and developments

    • 9.14 Santen Pharmaceuticals Co. Ltd.

      • 9.14.1 Company overview

      • 9.14.2 Company snapshot

      • 9.14.3 Operating business segments

      • 9.14.4 Product portfolio

      • 9.14.5 Business performance

      • 9.14.6 Key strategic moves and developments

    • 9.15 Spectra Vision Care Pvt. Ltd

      • 9.15.1 Company overview

      • 9.15.2 Company snapshot

      • 9.15.3 Operating business segments

      • 9.15.4 Product portfolio

      • 9.15.5 Business performance

      • 9.15.6 Key strategic moves and developments

    • 9.16 Sun Pharmaceuticals Industries Ltd

      • 9.16.1 Company overview

      • 9.16.2 Company snapshot

      • 9.16.3 Operating business segments

      • 9.16.4 Product portfolio

      • 9.16.5 Business performance

      • 9.16.6 Key strategic moves and developments

    • 9.17 Teva Pharmaceutical Industries Ltd

      • 9.17.1 Company overview

      • 9.17.2 Company snapshot

      • 9.17.3 Operating business segments

      • 9.17.4 Product portfolio

      • 9.17.5 Business performance

      • 9.17.6 Key strategic moves and developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 2. CONJUNCTIVITIS TREATMENT MARKET SIZE, FOR ANTIBIOTICS, BY REGION, 2021-2031 ($MILLION)
    TABLE 3. CONJUNCTIVITIS TREATMENT MARKET FOR ANTIBIOTICS, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 4. CONJUNCTIVITIS TREATMENT MARKET SIZE, FOR ANTIVIRAL, BY REGION, 2021-2031 ($MILLION)
    TABLE 5. CONJUNCTIVITIS TREATMENT MARKET FOR ANTIVIRAL, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 6. CONJUNCTIVITIS TREATMENT MARKET SIZE, FOR ANTI-ALLERGIC, BY REGION, 2021-2031 ($MILLION)
    TABLE 7. CONJUNCTIVITIS TREATMENT MARKET FOR ANTI-ALLERGIC, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 8. CONJUNCTIVITIS TREATMENT MARKET SIZE, FOR ARTIFICIAL TEARS, BY REGION, 2021-2031 ($MILLION)
    TABLE 9. CONJUNCTIVITIS TREATMENT MARKET FOR ARTIFICIAL TEARS, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 10. GLOBAL CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 11. CONJUNCTIVITIS TREATMENT MARKET SIZE, FOR ALLERGIC CONJUNCTIVITIS, BY REGION, 2021-2031 ($MILLION)
    TABLE 12. CONJUNCTIVITIS TREATMENT MARKET FOR ALLERGIC CONJUNCTIVITIS, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 13. GLOBAL ALLERGIC CONJUNCTIVITIS CONJUNCTIVITIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 14. CONJUNCTIVITIS TREATMENT MARKET, FOR SEASONAL ALLERGIC CONJUNCTIVITIS, BY REGION, 2021-2031 ($MILLION)
    TABLE 15. CONJUNCTIVITIS TREATMENT MARKET, FOR PERENNIAL ALLERGIC CONJUNCTIVITIS, BY REGION, 2021-2031 ($MILLION)
    TABLE 16. CONJUNCTIVITIS TREATMENT MARKET SIZE, FOR BACTERIAL CONJUNCTIVITIS, BY REGION, 2021-2031 ($MILLION)
    TABLE 17. CONJUNCTIVITIS TREATMENT MARKET FOR BACTERIAL CONJUNCTIVITIS, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 18. CONJUNCTIVITIS TREATMENT MARKET SIZE, FOR VIRAL CONJUNCTIVITIS, BY REGION, 2021-2031 ($MILLION)
    TABLE 19. CONJUNCTIVITIS TREATMENT MARKET FOR VIRAL CONJUNCTIVITIS, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 20. GLOBAL CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 21. CONJUNCTIVITIS TREATMENT MARKET SIZE, FOR HOSPITAL PHARMACY, BY REGION, 2021-2031 ($MILLION)
    TABLE 22. CONJUNCTIVITIS TREATMENT MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 23. CONJUNCTIVITIS TREATMENT MARKET SIZE, FOR RETAIL PHARMACY, BY REGION, 2021-2031 ($MILLION)
    TABLE 24. CONJUNCTIVITIS TREATMENT MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 25. CONJUNCTIVITIS TREATMENT MARKET SIZE, FOR ONLINE PHARMACY, BY REGION, 2021-2031 ($MILLION)
    TABLE 26. CONJUNCTIVITIS TREATMENT MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 27. CONJUNCTIVITIS TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
    TABLE 28. NORTH AMERICA CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 29. NORTH AMERICA CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 30. NORTH AMERICA ALLERGIC CONJUNCTIVITIS CONJUNCTIVITIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 31. NORTH AMERICA CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 32. NORTH AMERICA CONJUNCTIVITIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 33. U.S. CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 34. U.S. CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 35. U.S. CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 36. CANADA CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 37. CANADA CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 38. CANADA CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 39. MEXICO CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 40. MEXICO CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 41. MEXICO CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 42. EUROPE CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 43. EUROPE CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 44. EUROPE ALLERGIC CONJUNCTIVITIS CONJUNCTIVITIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 45. EUROPE CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 46. EUROPE CONJUNCTIVITIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 47. GERMANY CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 48. GERMANY CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 49. GERMANY CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 50. FRANCE CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 51. FRANCE CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 52. FRANCE CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 53. UK CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 54. UK CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 55. UK CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 56. ITALY CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 57. ITALY CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 58. ITALY CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 59. SPAIN CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 60. SPAIN CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 61. SPAIN CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 62. REST OF EUROPE CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 63. REST OF EUROPE CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 64. REST OF EUROPE CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 65. ASIA-PACIFIC CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 66. ASIA-PACIFIC CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 67. ASIA-PACIFIC ALLERGIC CONJUNCTIVITIS CONJUNCTIVITIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 68. ASIA-PACIFIC CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 69. ASIA-PACIFIC CONJUNCTIVITIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 70. JAPAN CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 71. JAPAN CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 72. JAPAN CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 73. CHINA CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 74. CHINA CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 75. CHINA CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 76. AUSTRALIA CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 77. AUSTRALIA CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 78. AUSTRALIA CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 79. INDIA CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 80. INDIA CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 81. INDIA CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 82. SOUTH KOREA CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 83. SOUTH KOREA CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 84. SOUTH KOREA CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 85. REST OF ASIA-PACIFIC CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 86. REST OF ASIA-PACIFIC CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 87. REST OF ASIA-PACIFIC CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 88. LAMEA CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 89. LAMEA CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 90. LAMEA ALLERGIC CONJUNCTIVITIS CONJUNCTIVITIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 91. LAMEA CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 92. LAMEA CONJUNCTIVITIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 93. BRAZIL CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 94. BRAZIL CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 95. BRAZIL CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 96. SAUDI ARABIA CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 97. SAUDI ARABIA CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 98. SAUDI ARABIA CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 99. SOUTH AFRICA CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 100. SOUTH AFRICA CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 101. SOUTH AFRICA CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 102. REST OF LAMEA CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 103. REST OF LAMEA CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
    TABLE 104. REST OF LAMEA CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 105.ABBVIE INC: COMPANY SNAPSHOT
    TABLE 106.ABBVIE INC: OPERATING SEGMENTS
    TABLE 107.ABBVIE INC: PRODUCT PORTFOLIO
    TABLE 108.ABBVIE INC: NET SALES,
    TABLE 109.ABBVIE INC: KEY STRATERGIES
    TABLE 110.AJANTA PHARMA LIMITED: COMPANY SNAPSHOT
    TABLE 111.AJANTA PHARMA LIMITED: OPERATING SEGMENTS
    TABLE 112.AJANTA PHARMA LIMITED: PRODUCT PORTFOLIO
    TABLE 113.AJANTA PHARMA LIMITED: NET SALES,
    TABLE 114.AJANTA PHARMA LIMITED: KEY STRATERGIES
    TABLE 115.AFT PHARMACEUTICALS: COMPANY SNAPSHOT
    TABLE 116.AFT PHARMACEUTICALS: OPERATING SEGMENTS
    TABLE 117.AFT PHARMACEUTICALS: PRODUCT PORTFOLIO
    TABLE 118.AFT PHARMACEUTICALS: NET SALES,
    TABLE 119.AFT PHARMACEUTICALS: KEY STRATERGIES
    TABLE 120.ALEMBIC PHARMACEUTICALS LTD: COMPANY SNAPSHOT
    TABLE 121.ALEMBIC PHARMACEUTICALS LTD: OPERATING SEGMENTS
    TABLE 122.ALEMBIC PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
    TABLE 123.ALEMBIC PHARMACEUTICALS LTD: NET SALES,
    TABLE 124.ALEMBIC PHARMACEUTICALS LTD: KEY STRATERGIES
    TABLE 125.BAUSCH HEALTH COMPANIES INC: COMPANY SNAPSHOT
    TABLE 126.BAUSCH HEALTH COMPANIES INC: OPERATING SEGMENTS
    TABLE 127.BAUSCH HEALTH COMPANIES INC: PRODUCT PORTFOLIO
    TABLE 128.BAUSCH HEALTH COMPANIES INC: NET SALES,
    TABLE 129.BAUSCH HEALTH COMPANIES INC: KEY STRATERGIES
    TABLE 130.CIPLA, INC.: COMPANY SNAPSHOT
    TABLE 131.CIPLA, INC.: OPERATING SEGMENTS
    TABLE 132.CIPLA, INC.: PRODUCT PORTFOLIO
    TABLE 133.CIPLA, INC.: NET SALES,
    TABLE 134.CIPLA, INC.: KEY STRATERGIES
    TABLE 135.GREVIS PHARMACEUTICAL PRIVATE LIMITED: COMPANY SNAPSHOT
    TABLE 136.GREVIS PHARMACEUTICAL PRIVATE LIMITED: OPERATING SEGMENTS
    TABLE 137.GREVIS PHARMACEUTICAL PRIVATE LIMITED: PRODUCT PORTFOLIO
    TABLE 138.GREVIS PHARMACEUTICAL PRIVATE LIMITED: NET SALES,
    TABLE 139.GREVIS PHARMACEUTICAL PRIVATE LIMITED: KEY STRATERGIES
    TABLE 140.INDOCO REMEDIES LTD.: COMPANY SNAPSHOT
    TABLE 141.INDOCO REMEDIES LTD.: OPERATING SEGMENTS
    TABLE 142.INDOCO REMEDIES LTD.: PRODUCT PORTFOLIO
    TABLE 143.INDOCO REMEDIES LTD.: NET SALES,
    TABLE 144.INDOCO REMEDIES LTD.: KEY STRATERGIES
    TABLE 145.JABS BIOTECH PVT. LTD.: COMPANY SNAPSHOT
    TABLE 146.JABS BIOTECH PVT. LTD.: OPERATING SEGMENTS
    TABLE 147.JABS BIOTECH PVT. LTD.: PRODUCT PORTFOLIO
    TABLE 148.JABS BIOTECH PVT. LTD.: NET SALES,
    TABLE 149.JABS BIOTECH PVT. LTD.: KEY STRATERGIES
    TABLE 150.JAWA PHARMACEUTICALS PVT. LTD: COMPANY SNAPSHOT
    TABLE 151.JAWA PHARMACEUTICALS PVT. LTD: OPERATING SEGMENTS
    TABLE 152.JAWA PHARMACEUTICALS PVT. LTD: PRODUCT PORTFOLIO
    TABLE 153.JAWA PHARMACEUTICALS PVT. LTD: NET SALES,
    TABLE 154.JAWA PHARMACEUTICALS PVT. LTD: KEY STRATERGIES
    TABLE 155.JOHNSON & JOHNSON SERVICES INC: COMPANY SNAPSHOT
    TABLE 156.JOHNSON & JOHNSON SERVICES INC: OPERATING SEGMENTS
    TABLE 157.JOHNSON & JOHNSON SERVICES INC: PRODUCT PORTFOLIO
    TABLE 158.JOHNSON & JOHNSON SERVICES INC: NET SALES,
    TABLE 159.JOHNSON & JOHNSON SERVICES INC: KEY STRATERGIES
    TABLE 160.NOVARTIS AG: COMPANY SNAPSHOT
    TABLE 161.NOVARTIS AG: OPERATING SEGMENTS
    TABLE 162.NOVARTIS AG: PRODUCT PORTFOLIO
    TABLE 163.NOVARTIS AG: NET SALES,
    TABLE 164.NOVARTIS AG: KEY STRATERGIES
    TABLE 165.OCULAR THERAPEUTICS, INC: COMPANY SNAPSHOT
    TABLE 166.OCULAR THERAPEUTICS, INC: OPERATING SEGMENTS
    TABLE 167.OCULAR THERAPEUTICS, INC: PRODUCT PORTFOLIO
    TABLE 168.OCULAR THERAPEUTICS, INC: NET SALES,
    TABLE 169.OCULAR THERAPEUTICS, INC: KEY STRATERGIES
    TABLE 170.SANTEN PHARMACEUTICALS CO. LTD.: COMPANY SNAPSHOT
    TABLE 171.SANTEN PHARMACEUTICALS CO. LTD.: OPERATING SEGMENTS
    TABLE 172.SANTEN PHARMACEUTICALS CO. LTD.: PRODUCT PORTFOLIO
    TABLE 173.SANTEN PHARMACEUTICALS CO. LTD.: NET SALES,
    TABLE 174.SANTEN PHARMACEUTICALS CO. LTD.: KEY STRATERGIES
    TABLE 175.SPECTRA VISION CARE PVT. LTD: COMPANY SNAPSHOT
    TABLE 176.SPECTRA VISION CARE PVT. LTD: OPERATING SEGMENTS
    TABLE 177.SPECTRA VISION CARE PVT. LTD: PRODUCT PORTFOLIO
    TABLE 178.SPECTRA VISION CARE PVT. LTD: NET SALES,
    TABLE 179.SPECTRA VISION CARE PVT. LTD: KEY STRATERGIES
    TABLE 180.SUN PHARMACEUTICALS INDUSTRIES LTD: COMPANY SNAPSHOT
    TABLE 181.SUN PHARMACEUTICALS INDUSTRIES LTD: OPERATING SEGMENTS
    TABLE 182.SUN PHARMACEUTICALS INDUSTRIES LTD: PRODUCT PORTFOLIO
    TABLE 183.SUN PHARMACEUTICALS INDUSTRIES LTD: NET SALES,
    TABLE 184.SUN PHARMACEUTICALS INDUSTRIES LTD: KEY STRATERGIES
    TABLE 185.TEVA PHARMACEUTICAL INDUSTRIES LTD: COMPANY SNAPSHOT
    TABLE 186.TEVA PHARMACEUTICAL INDUSTRIES LTD: OPERATING SEGMENTS
    TABLE 187.TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO
    TABLE 188.TEVA PHARMACEUTICAL INDUSTRIES LTD: NET SALES,
    TABLE 189.TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY STRATERGIES

  • LIST OF FIGURES

  • FIGURE 1.CONJUNCTIVITIS TREATMENT MARKET SEGMENTATION
    FIGURE 2.CONJUNCTIVITIS TREATMENT MARKET,2021-2031
    FIGURE 3.CONJUNCTIVITIS TREATMENT MARKET,2021-2031
    FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
    FIGURE 5.PORTER FIVE-1
    FIGURE 6.PORTER FIVE-2
    FIGURE 7.PORTER FIVE-3
    FIGURE 8.PORTER FIVE-4
    FIGURE 9.PORTER FIVE-5
    FIGURE 10.TOP PLAYER POSITIONING
    FIGURE 11.CONJUNCTIVITIS TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
    FIGURE 12.CONJUNCTIVITIS TREATMENT MARKET,BY DRUG CLASS,2021(%)
    FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ANTIBIOTICS CONJUNCTIVITIS TREATMENT MARKET,2021-2031(%)
    FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ANTIVIRAL CONJUNCTIVITIS TREATMENT MARKET,2021-2031(%)
    FIGURE 15.COMPARATIVE SHARE ANALYSIS OF ANTI-ALLERGIC CONJUNCTIVITIS TREATMENT MARKET,2021-2031(%)
    FIGURE 16.COMPARATIVE SHARE ANALYSIS OF ARTIFICIAL TEARS CONJUNCTIVITIS TREATMENT MARKET,2021-2031(%)
    FIGURE 17.CONJUNCTIVITIS TREATMENT MARKET,BY DISEASE TYPE,2021(%)
    FIGURE 18.COMPARATIVE SHARE ANALYSIS OF ALLERGIC CONJUNCTIVITIS CONJUNCTIVITIS TREATMENT MARKET,2021-2031(%)
    FIGURE 19.COMPARATIVE SHARE ANALYSIS OF BACTERIAL CONJUNCTIVITIS CONJUNCTIVITIS TREATMENT MARKET,2021-2031(%)
    FIGURE 20.COMPARATIVE SHARE ANALYSIS OF VIRAL CONJUNCTIVITIS CONJUNCTIVITIS TREATMENT MARKET,2021-2031(%)
    FIGURE 21.CONJUNCTIVITIS TREATMENT MARKET,BY DISTRIBUTION CHANNEL,2021(%)
    FIGURE 22.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACY CONJUNCTIVITIS TREATMENT MARKET,2021-2031(%)
    FIGURE 23.COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACY CONJUNCTIVITIS TREATMENT MARKET,2021-2031(%)
    FIGURE 24.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACY CONJUNCTIVITIS TREATMENT MARKET,2021-2031(%)
    FIGURE 25.CONJUNCTIVITIS TREATMENT MARKET BY REGION,2021
    FIGURE 26.U.S. CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 27.CANADA CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 28.MEXICO CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 29.GERMANY CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 30.FRANCE CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 31.UK CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 32.ITALY CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 33.SPAIN CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 34.REST OF EUROPE CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 35.JAPAN CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 36.CHINA CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 37.AUSTRALIA CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 38.INDIA CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 39.SOUTH KOREA CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 40.REST OF ASIA-PACIFIC CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 41.BRAZIL CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 42.SAUDI ARABIA CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 43.SOUTH AFRICA CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 44.REST OF LAMEA CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
    FIGURE 45. TOP WINNING STRATEGIES, BY YEAR
    FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT
    FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY
    FIGURE 48.PRODUCT MAPPING OF TOP 10 PLAYERS
    FIGURE 49.COMPETITIVE DASHBOARD
    FIGURE 50.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
    FIGURE 51.ABBVIE INC.: NET SALES ,($MILLION)
    FIGURE 52.AJANTA PHARMA LIMITED.: NET SALES ,($MILLION)
    FIGURE 53.AFT PHARMACEUTICALS.: NET SALES ,($MILLION)
    FIGURE 54.ALEMBIC PHARMACEUTICALS LTD.: NET SALES ,($MILLION)
    FIGURE 55.BAUSCH HEALTH COMPANIES INC.: NET SALES ,($MILLION)
    FIGURE 56.CIPLA, INC..: NET SALES ,($MILLION)
    FIGURE 57.GREVIS PHARMACEUTICAL PRIVATE LIMITED.: NET SALES ,($MILLION)
    FIGURE 58.INDOCO REMEDIES LTD..: NET SALES ,($MILLION)
    FIGURE 59.JABS BIOTECH PVT. LTD..: NET SALES ,($MILLION)
    FIGURE 60.JAWA PHARMACEUTICALS PVT. LTD.: NET SALES ,($MILLION)
    FIGURE 61.JOHNSON & JOHNSON SERVICES INC.: NET SALES ,($MILLION)
    FIGURE 62.NOVARTIS AG.: NET SALES ,($MILLION)
    FIGURE 63.OCULAR THERAPEUTICS, INC.: NET SALES ,($MILLION)
    FIGURE 64.SANTEN PHARMACEUTICALS CO. LTD..: NET SALES ,($MILLION)
    FIGURE 65.SPECTRA VISION CARE PVT. LTD.: NET SALES ,($MILLION)
    FIGURE 66.SUN PHARMACEUTICALS INDUSTRIES LTD.: NET SALES ,($MILLION)
    FIGURE 67.TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES ,($MILLION)

 
 

This section provides opinions of the CXOs of key companies operating in the conjunctivitis treatment market. According to the CXOs, the adoption of new treatments is expected to increase due to rise in prevalence of conjunctivitis. As per the CXOs, conjunctivitis treatment is expected to witness high adoption in the near future, owing to increase in number of R&D activities by the market players across the globe. In addition, the market is exhibiting high growth rate, owing to surge in awareness about conjunctivitis.

By region, North America is expected to remain dominant during the forecast period, due to local presence of large in-house conjunctivitis drug manufacturers like AbbVie, Akon Pharmaceuticals, Alcon Pharmaceuticals, and Bausch + Lomb. Moreover, Asia-Pacific registered highest CAGR and is expected to continue this trend throughout the forecast period, owing to improvement in healthcare facilities, rise in disposable income, increase in adoption of conjunctivitis treatment, and rapid improvement in economic conditions.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The total market value of conjunctivitis treatment market is $4213.01 million in 2021.

A. The key trends in the conjunctivitis treatment market are by an increasing prevalence of allergic conjunctivitis and rise in exposure to allergens.

A. Asia-Pacific is expected to register the highest CAGR of 4.4% from 2022 to 2031, owing to increase in product launch in region, rise in healthcare expenditures and presence of high population base.

A. The market value of conjunctivitis treatment market in 2022 was $4373.1 million.

A. The top companies that hold the market share in conjunctivitis treatment market are AbbVie Inc., Ajanta Pharma Limited, AFT pharmaceuticals, Alembic Pharmaceuticals Ltd, Bausch Health Companies Inc , Cipla, Inc., Grevis Pharmaceutical Private Limited , Indoco Remedies Ltd., Jabs Biotech Pvt. Ltd., JAWA Pharmaceuticals Pvt. Ltd, Johnson & Johnson Services Inc., , Novartis AG, , Ocular Therapeutics, Inc., Santen Pharmaceuticals Co. Ltd., Spectra Vision Care Pvt. Ltd, Sun Pharmaceuticals Industries Ltd and Teva Pharmaceutical Industries Ltd.

A. The forecast period in the report is from 2022 to 2031.

A. North America is the largest regional market for Conjunctivitis Treatment.

A. The forecast period in the report is from 2022 to 2031.

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Sample
RELATED TAGS

Purchase Full Report of
Conjunctivitis Treatment Market

Start reading instantly.
This Report and over 67,068+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,570
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Sep 2023 - Sep 2024)
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Sep 2023 - Sep 2024)
  • Single User
  • $5,730
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Sep 2023 - Sep 2024)
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Sep 2023 - Sep 2024)

  • Enterprise
    License/PDF

  • $9,600
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Sep 2023 - Sep 2024)

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers